# Marcos Milla

> Marcos Milla is a Series A investor at Samsara BioCapital backing Biotechnology and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital)
- Location: San Diego, United States
- Total investments: 5
- Last investment: Apr 2024
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/marcos-milla-0792843/

Marcos Milla is a Series A investor at Samsara BioCapital in San Diego focused on Biotechnology and Health Care. Marcos Milla is the Venture Partner at Samsara BioCapital

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Health Care | 2 | 40% |
| Biopharma | 1 | 20% |
| Therapeutics | 1 | 20% |
| Pharmaceutical | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series B | 2 | 40% |
| Seed | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 40% |
| Switzerland | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Enlaza Therapeutics | Enlaza Therapeutics is a biotechnology research company. It was founded in 2020 and is headquartered in La Jolla, California. | $100M | Series A | Apr 30, 2024 |  |
| Tentarix Biotherapeutics | Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies. | $35M | Series B | Sep 06, 2023 |  |
| Enlaza Therapeutics | Enlaza Therapeutics is a biotechnology research company. It was founded in 2020 and is headquartered in La Jolla, California. | $61M | Seed | Oct 12, 2022 |  |
| ImmunOs Therapeutics | ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease. | $72.9M | Series B | Jun 07, 2022 |  |
| Tentarix Biotherapeutics | Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies. | $50M | Series A | Oct 14, 2021 |  |

5 of 5 investments shown.

## Co-investors
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 4 deals together
- [Lightspeed Venture Partners](https://shizune.co/investors/profile/lightspeed-venture-partners) — VC Fund, 3 deals together
- [Avalon Ventures](https://shizune.co/investors/profile/avalon-ventures) — VC Fund, 2 deals together
- [Frazier Life Sciences](https://shizune.co/investors/profile/frazier-life-sciences) — VC Fund, 2 deals together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 2 deals together
- [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 2 deals together

## About Samsara BioCapital

VC Fund · Palo Alto, United States

Samsara Biocapital provides investment advisory services to help entrepreneurs turn their own ideas and visions into successful companies. Samsara BioCapital, as a results-driven organization, is always looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level. Samsara BioCapital promotesbiotech innovation and collaborates with inspiring companies as they develop important and innovative new therapies.

5 contacts available at Samsara BioCapital.

| Name | Title | Profile |
| --- | --- | --- |
| Abraham Bassan | Partner | https://shizune.co/investors/profile/abraham-bassan |
| Michael Dybbs | Partner | https://shizune.co/investors/profile/mike-dybbs |
| Christian Richard | Head of Public Research | https://shizune.co/investors/profile/christian-m-richard |
| Marcos Milla | Venture Partner | https://shizune.co/investors/profile/marcos-milla |
| Srini Akkaraju | Founder | https://shizune.co/investors/profile/srini-akkaraju |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Marcos Milla invest in?

Marcos Milla invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Marcos Milla last invest?

The most recent investment recorded for Marcos Milla closed in Apr 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co